ストックスクリーナーアプリを入手
0.4901
4.30%
-0.022
Enlivex Ltd (ENLV) 最新ニュース
Enlivex Therapeutics outlines its immunotherapy approach as a clinical-stage biotech - AD HOC NEWS
Enlivex (ENLV) Implements Reverse Stock Split - GuruFocus
Enlivex announces 1-for-15 reverse stock split effective Wednesday By Investing.com - Investing.com Australia
Enlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026 - The Manila Times
Enlivex (Nasdaq: ENLV) enacts 1-for-15 reverse split and cuts share count - Stock Titan
Enlivex to shrink share count 15-to-1 on July 9 as Nasdaq trading continues - Stock Titan
Discontinued operations of Enlivex Ltd. – DUS:1BT - TradingView
Preferred dividends of Enlivex Ltd. – DUS:1BT - TradingView
Enterprise value to revenue forward of Enlivex Ltd. – DUS:1BT - TradingView
Price to sales forward of Enlivex Ltd. – NASDAQ:ENLV - TradingView
Price to book forward of Enlivex Ltd. – NASDAQ:ENLV - TradingView
Enterprise value to EBIT forward of Enlivex Ltd. – NASDAQ:ENLV - TradingView
Enterprise value to EBITDA forward of Enlivex Ltd. – DUS:1BT - TradingView
Enlivex Ltd. Earnings and Revenue – DUS:1BT - TradingView
Enlivex Ltd. Actuals & Estimates (NASDAQ:ENLV) - TradingView
ENLV Forecast — Price Target — Prediction for 2027 - TradingView
1BT Forecast — Price Target — Prediction for 2027 - TradingView
Enlivex Therapeutics Ltd (ENLV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gate exchange lists Enlivex treasury asset RAIN token - Investing.com
Gate exchange lists Enlivex treasury asset RAIN token By Investing.com - Investing.com India
Enlivex’s Primary Treasury Asset RAIN Token set for Listing on Major Exchange Gate - TipRanks
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume - The Manila Times
Enlivex (NASDAQ: ENLV) highlights RAIN listing on Gate and $1.14B treasury - Stock Titan
Enlivex token gets Gate listing, widening access to its $1.14B treasury asset - Stock Titan
Enlivex Ltd. (ENLV) Edges Higher – Key Levels to WatchPrice Target - dars.gov.et
Enlivex Therapeutics Ltd (ENLV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enlivex Values RAIN Token Treasury at $1.14 Billion as of June 20, 2026 - TipRanks
Form 6K Enlivex Therapeutics Ltd For: 22 June By Investing.com - Investing.com South Africa
Enlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion - The Manila Times
[6-K] Enlivex Ltd. Current Report (Foreign Issuer) | ENLV SEC FilingForm 6-K - Stock Titan
Enlivex Reports $1.14 Billion Value in RAIN Token Holdings as of June 20, 2026 - Quiver Quantitative
Enlivex says its RAIN token treasury is worth about $1.14 billion - Stock Titan
ENLV Stockweekly outlook with no verified hook - AD HOC NEWS
Enlivex Therapeutics Ltd (ENLV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enlivex Therapeutics Ltd (ENLV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enlivex Therapeutics Ltd (ENLV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enlivex Therapeutics Ltd (ENLV) Institutional Confidence - TradingKey
Enlivex Therapeutics Ltd (ENLV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Enlivex Therapeutics Ltd (ENLV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enlivex Therapeutics Ltd (ENLV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ENLV Q4 2025 Earnings: Massive EPS Miss Highlights Challenging QuarterProfit Announcement - newsline.com
Enlivex Secures Australian Patent for Allocetra in Osteoarthritis Treatment - GuruFocus
Enlivex (ENLV) Slips Slightly as Stock Tests Key Support Near $0.63Positive Gamma - newsline.com
Enlivex receives Australian patent for osteoarthritis treatment - Investing.com
Enlivex receives Australian patent for osteoarthritis treatment By Investing.com - Investing.com Canada
Enlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis - The Manila Times
Australian patent backs Enlivex cell therapy for knee osteoarthritis to 2040 - Stock Titan
Enlivex (ENLV) Shares Slide Over 6% as Stock Tests Key Support at $0.64Last Point Support - newsline.com
ENLV Q4 2025 Earnings: Deep Losses and Clinical Progress Amid Severe EPS MissEarnings Revision Upgrade - newsline.com
Enlivex Therapeutics stock (IL0011283620): Data monitoring, Nasdaq notice and next steps for investo - Ad-hoc-news.de
ENLV Q4 2025 Earnings: Significant EPS Miss Reflects Clinical-Stage DevelopmentHigh Estimate Range - newsline.com
Number of shareholders of Enlivex Ltd. – LSX:A119KH - TradingView
RAIN Highlights $200M Ecosystem Commitment, $100M Liquidity Expansion, and World Cup Growth Strategy Ahead of Version 2 Launch - GlobeNewswire Inc.
ENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026 - marketscreener.com
Enlivex brings longevity‑prediction markets pitch to $18T Paris summit - Stock Titan
1.88%
2.71%
大文字化:
|
ボリューム (24 時間):